Profiel
Mr. Markus Peter is a Head of Investment & Products at Bellevue Asset Management AG.
Mr. Peter previously worked in various functions for Julius Baer Asset Management.
From 1995-2000 he was a Treasury and Specialty Financing Associate for IBM, and from 1990-1995 he worked as an Equity Derivatives Trader for Swiss Bank Union.
Mr. Peter holds a Master's degree in Business Economics from the University of St. Gallen (HSG).
Actieve functies van Markus Peter
| Bedrijven | Functie | Begin |
|---|---|---|
| BELLEVUE GROUP AG | Chief Investment Officer | 01-03-2024 |
Bellevue Asset Management AG
 Bellevue Asset Management AG Investment ManagersFinance Bellevue Asset Management AG (Bellevue AM) is the wholly-owned asset management subsidiary of Bellevue Group AG (SWX: BBN), an independent Swiss financial group. The firm is headquartered in Küsnacht, Switzerland and has additional offices in Germany, Austria and Luxembourg. Founded in 1993, Bellevue AM provides a diverse spectrum of top-tier investment solutions with a focus on global healthcare sector for private and institutional clients. They offer their flagship investment vehicle, the listed investment company BB Biotech AG. | Portefeuillebeheerder-Aandelen | 01-01-2009 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| BELLEVUE GROUP AG | Finance |
| Bedrijven in privébezit | 1 |
|---|---|
Bellevue Asset Management AG
Bellevue Asset Management AG Investment ManagersFinance Bellevue Asset Management AG (Bellevue AM) is the wholly-owned asset management subsidiary of Bellevue Group AG (SWX: BBN), an independent Swiss financial group. The firm is headquartered in Küsnacht, Switzerland and has additional offices in Germany, Austria and Luxembourg. Founded in 1993, Bellevue AM provides a diverse spectrum of top-tier investment solutions with a focus on global healthcare sector for private and institutional clients. They offer their flagship investment vehicle, the listed investment company BB Biotech AG. | Finance |
